Physician profile
Daniel Noall Bennett
NPI 1013200997
$12,065.43
in general payments reported to CMS, 2019-2025
32 companies · $758 in 2025
The $758 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,237 · 2020: $1,572 · 2021: $792 · 2022: $5,635 · 2023: $823 · 2024: $1,248 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,829.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,944.87 | 2021-2024 | Corevalve Evolut R, Flexcath Contour, Flexcath Advance |
| Edwards Lifesciences Corporation | $2,227.18 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal |
| Boston Scientific Corporation | $2,047.26 | 2019-2025 | Rotapro, Watchman Access System, Watchman Flx |
| Abbott Laboratories | $538.72 | 2019-2025 | Mitraclip, Portico, Amplatzer |
| Novartis Pharmaceuticals Corporation | $466.42 | 2019-2025 | |
| Amgen INC. | $356.71 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $349.23 | 2019-2022 | |
| Pfizer INC. | $319.88 | 2019-2025 | |
| Abiomed | $291.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.01 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $219.93 | 2019-2025 | Camzyos |
| Actelion Pharmaceuticals US, INC. | $199.24 | 2020-2024 | Opsumit, Uptravi |
| Medtronic Vascular, INC. | $151.00 | 2019-2020 | |
| Baxter Healthcare | $123.34 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Chiesi USA, INC. | $76.90 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $68.51 | 2021 | |
| Amarin Pharma, INC. | $67.32 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $51.83 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $34.32 | 2022-2025 | Verquvo |
| Biosense Webster, INC. | $33.67 | 2025 | Carto 3 |
| Teleflex LLC | $26.59 | 2021-2023 | Trapliner |
| Cvrx, INC. | $26.40 | 2025 | Barostim Neo System |
| Heartflow, INC. | $22.43 | 2025 | |
| Cardinal Health 200 LLC | $21.25 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $20.27 | 2024 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $19.38 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $18.01 | 2024 | Inpefa |
| Philips North America LLC | $16.99 | 2025 | Igt Devices Undivided |
| Altathera Pharmaceuticals LLC | $16.93 | 2021 | |
| Esperion Therapeutics, INC. | $14.30 | 2021 | |
| Gilead Sciences, INC. | $14.16 | 2019 | |
| Analog Devices INC. | $14.02 | 2024 | Sensinel Cpm Wearable |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.